Karen Cerosaletti

机构：Virginia Mason Medical Center, Benaroya Research Institute · ORCID：0000-0002-7403-6239

发表论文 114 篇 · 总被引 8505 次 · h-index 38

代表论文

• A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab (2023 · Diabetologia · 被引 60)
• GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes (2024 · JCI Insight · 被引 53)
• Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes (2023 · JCI Insight · 被引 28)
• PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses (2023 · eLife · 被引 26)
• IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease (2024 · Journal of Clinical Investigation · 被引 18)
• Identification of a novel PDC-E2 epitope in primary biliary cholangitis: Application for engineered Treg therapy (2024 · Journal of Autoimmunity · 被引 10)